NewAmsterdam Pharma Stock (NASDAQ:NAMS)

Forecast Revenue Ownership Financials Chart

Previous Close

$26.90

52W Range

$14.06 - $27.35

50D Avg

$23.48

200D Avg

$21.39

Market Cap

$3.00B

Avg Vol (3M)

$920.16K

Beta

-0.01

Div Yield

-

NAMS Company Profile

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

NL

Employees

68

IPO Date

Feb 09, 2021

Website

NAMS Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 22
License Revenue	$93.50M

Fiscal year ends in Dec 24 | Currency in USD

NAMS Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$45.56M	$12.76M	$95.91M
Operating Income	$-176.29M	$-165.73M	$-3.32M
Net Income	-	$-176.94M	$-21.14M
EBITDA	-	$-176.86M	$-3.31M
Basic EPS	$-2.56	$-2.15	$-1.11
Diluted EPS	$-2.56	$-2.15	$-1.11

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
STRO	Sutro Biopharma, Inc.
TYRA	Tyra Biosciences, Inc.
NUVL	Nuvalent, Inc.
HLVX	HilleVax, Inc.
PROK	ProKidney Corp.
CNTA	Centessa Pharmaceuticals plc
PEPG	PepGen Inc.